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Beginning with the physical barrier 
presented by the epithelium, 
infectious agents such as viruses 
and bacteria encounter an 
array of cellular and molecular 
countermeasures that evolved 
within the host to resist them. 
Host immune responses are of two 
types, termed innate and adaptive. 
Immediate defensive responses, 
which include inflammation, 
phagocytosis of pathogens, and 
recruitment of a variety of immune 
cells, are employed against all 
classes of microbe, irrespective of 
prior exposure, and are collectively 
termed the innate immune response. 
Innate immunity is evolutionarily 
ancient, and selected mechanisms 
are known to be conserved from 
plants to humans. In contrast, 
the adaptive immune response is 
mobilized over a more protracted 
timescale, is influenced by prior 
exposure, and, by virtue of antigen-
specific receptors generated through 
somatic DNA recombination within 
lymphoid clones, is highly specific 
at the molecular level, often to the 
point of specificity for a particular 
microbial species. Adaptive immunity 
evolved relatively recently and exists 
only in vertebrates. In mammals, the 
immune response encompasses the 
innate and adaptive responses, and, 
although cross-talk occurs between 
them, each can be carried out 
independently by distinct cellular  
and molecular mechanisms.
Both innate and adaptive immune 
responses depend on distinguishing 
self from non-self. For the innate 
response, a family of cellular 
receptors called Toll-like receptors 
(TLRs), which recognize molecules 
unique to microbes, constitutes the 
primary strategy for self versus non-
self discrimination. The study of TLRs 
as critical innate immune activators 
began with classical genetic studies 
that led to the identification of 
Toll-like receptor 4 (TLR4) as the 
receptor for lipopolysaccharide 
(LPS), a structural component of the 
outer membrane of Gram-negative 
Primer bacteria. Recognition of a total of 10 human and 12 mouse TLRs and their 
distinct microbial ligands followed 
soon after. The family of TLRs is 
now known to represent the major 
microbe-sensing system in mammals, 
detecting molecules derived from 
viruses, fungi, bacteria, and protozoa. 
Intracellular NOD-like receptors, 
receptors of the retinoic acid-
inducible gene I (RIG-I)-like helicase 
family, C-type lectin receptors, and 
a subset of the eIF2a kinases also 
act as microbe sensors. However, 
some of these sensing systems 
display TLR dependence, and none 
is able to fully compensate for a 
lack of TLR signaling, a condition 
that results in severe immune 
deficiency. Here, we review basic 
concepts of TLR biology, including 
the ligands, structural properties, 
cellular localization, and signaling 
pathways of these receptors. We 
discuss physiological responses to 
TLR activation, collectively termed 
the inflammatory response, and 
the connection between TLRs and 
autoimmune and autoinflammatory 
disease.
TLRs sense molecular signatures 
of microbes
TLRs are single-pass type 
I transmembrane-spanning 
proteins characterized by multiple 
extracellular leucine-rich repeats 
(LRRs) and a single intracellular 
Toll/interleukin-1 (IL-1) receptor (TIR) 
domain that is homologous to the 
intracellular domain of IL-1 receptor 
family members. In mice and humans 
combined there are 13 paralogous 
TLRs; 10 in humans and 12 in mice. 
Each recognizes and is activated 
by a small collection of microbe-
derived molecules, as determined 
through studies of targeted mutant 
mice lacking individual TLRs. 
Lipopeptides and other components 
of Gram-positive bacterial cells 
activate TLR2 in conjunction with 
either TLR1 or TLR6; LPS is detected 
by TLR4 (discovered by forward 
genetic studies as mentioned 
above); flagellin is detected by 
TLR5; poly I:C, a double-stranded 
RNA (dsRNA) analog, is detected 
by TLR3; unmethylated DNA and 
CpG-oligodeoxynucleotides (CpG-
DNA) are detected by TLR9; and 
single-stranded RNA and its synthetic 
analogs resiquimod, imiquimod, and 
loxoribine activate TLR7 (Figure 1A). The ligands for TLR8, TLR10 (only 
present in humans), and TLR11–13 
(only present in mice) remain 
unknown.
Seven TLRs have recognized 
ligands, and collectively these 
receptors detect all known 
infectious agents via their clusters 
of extracellular LRRs. The LRR 
module has been conserved in 
plants, insects, and mammals 
as a recognition and binding 
element for microbial molecules. 
In some cases, TLR ligands must 
initially or exclusively interact with 
transmembrane or membrane-
associated accessory proteins 
or co-receptors that affect the 
conformation of TLRs and thereby 
permit downstream signaling. 
These accessory proteins include 
MD-2 (which is necessary for 
TLR4 to bind LPS) and CD14 
(which allows TLR4 to distinguish 
between smooth (containing long 
O-polysaccharide chains) and rough 
(lacking O-polysaccharide chains) 
LPS chemotypes). CD14 and CD36 
both serve to augment, but are 
not absolutely required for, TLR2 
signaling. Granulin and high mobility 
group (HMG) B proteins have been 
proposed to deliver CpG-DNA to 
TLR9 through an ability to bind 
simultaneously to both CpG-DNA 
and TLR9.
The three-dimensional crystal 
structures of the ectodomains 
of TLR3, TLR4, TLR2–TLR6, and 
TLR2–TLR1 revealed a curved 
solenoid shape characteristic of 
LRR-containing proteins. TLRs 
form homodimers or heterodimers 
induced by the simultaneous binding 
of ligands to residues in the LRRs 
of distinct receptor chains. TLRs 
utilize diverse strategies for ligand 
recognition (Figure 1B). For example, 
TLR3 interacts with dsRNA using 
lateral surface-exposed sites on the 
concave side of each ectodomain. 
In contrast, TLR2–TLR1 and TLR2–
TLR6 heterodimers interact with 
lipopeptides via a hydrophobic pocket 
formed by residues on the convex 
side of each ectodomain near the 
center of the dimer. In the case of 
TLR4, the interface between TLR4 and 
its required co-receptor MD-2 must 
first form, followed by LPS-induced 
dimerization of two TLR4–MD-2 
dimers. LPS simultaneously contacts 
a hydrophobic pocket within MD-2  
(from one dimer) and the convex 
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Figure 1. TLR ligands and interactions with receptors.  
(A) Three-dimensional structures of the lipopeptide Pam2CSK4 (from 3A79), double-stranded RNA (from 3CIY), LPS (from 3FXI), flagellin (3K8V), 
a tRNA as a model of single-stranded RNA (2L9E), and unmethylated CpG-DNA (from 3QMB). Gray, blue, red, orange, and yellow spheres 
represent carbon, nitrogen, oxygen, phosphorus, and sulfur atoms, respectively. The chemical structures of resiquimod, imiquimod, and 
loxoribine are also shown. Possible microbial sources of ligands are indicated. (B) Structures of TLR2–TLR6–Pam2CSK4 lipopeptide (3A79), 
TLR2–TLR1–Pam3CSK4 lipopeptide (2Z7X), TLR3-dsRNA (3CIY), and TLR4–MD-2–LPS (3FXI). Side view (upper panels) and top view (lower 
panels) are shown. Protein Databank ID numbers are indicated in parentheses. (All figures were generated with UCSF Chimera.)surface of TLR4 (from the other 
dimer). Despite the variation in modes 
of ligand recognition, all known TLR 
dimer structures display the same 
arrangement, with the two carboxy-
terminal tails closely juxtaposed and 
the amino termini at opposite ends of 
the dimer. This conformation may be 
required to bring the intracellular TIR 
domains into close proximity to initiate 
signaling.
The response elicited by TLR 
activation: inflammation
TLRs act principally to initiate 
an innate immune response, and 
inflammation is the central hallmark 
of this response. TLRs have also 
been described as ‘necessary’ or 
‘required’ for an adaptive immune 
response. This conclusion may 
initially have been prompted by the 
long-known fact that molecules 
ultimately recognized as TLR ligands, including LPS, poly I:C, and CpG-
DNA, do indeed enhance the adaptive 
immune response, i.e. have adjuvant 
properties. However, there remains no 
evidence of adaptive immune failure 
in the absence of TLR signaling. 
To the contrary, robust adaptive 
immune responses, including 
antibody production and activation 
of cytotoxic T lymphocytes, occur 
after infection in animals that lack 
TLR signaling. Classical adjuvants, 
including Freund’s complete 
adjuvant, elicit strong antibody 
responses in animals that lack TLR 
signaling. Moreover, some adjuvants 
that contain TLR ligands are able to 
initiate adaptive immune responses in 
the absence of TLR signaling as well, 
suggesting that they have multiple 
mechanisms of action. Adaptive 
immune responses are elicited by a 
range of mechanisms, and not merely 
by TLR signaling.Systemic inflammation induced 
by TLRs results primarily from the 
activation of macrophages and 
neutrophils, cell types with specialized 
functions in innate immunity (Figure 
2). TLR ligands cause macrophages 
to produce inflammatory cytokines 
such as tumor necrosis factor 
(TNF)-a, IL-1 and IL-6. Cytokines 
act on immune cells by binding to 
specific cell-surface receptors, which 
elicit complex cellular responses. 
Inflammatory cytokines produced by 
activated macrophages near the site 
of infection promote inflammation 
by increasing the permeability 
of the vascular endothelium to 
plasma, increasing the propensity 
of neutrophils to bind to the 
microvascular endothelial surface and 
move out of the vascular system by 
diapedesis, and causing the release 
of antimicrobial peptides and small 
molecules such as leukotrienes 
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Pathogens, such as bacteria, may enter the host through a breached epithelial barrier, 
leading to activation of macrophage TLRs by pathogen-derived molecules, including LPS. 
TLR signaling leads to the production of inflammatory cytokines, which act near the site of 
infection to recruit neutrophils and induce neutrophil production of antimicrobial molecules, 
including peptides, reactive oxygen species (e.g. H2O2 and superoxide anion), and 
leukotrienes. Cytokines also travel throughout the body and induce systemic effects. Both 
macrophages and neutrophils act to limit infection by phagocytosis of pathogens.(lipid mediators of inflammation) 
and reactive oxygen species from 
neutrophils (Figure 2). Operating 
at sites distant from the infection, 
cytokines also mediate systemic 
effects, such as fever, and may 
cause generalized vasodilation and 
reduce the contractile strength of the 
heart. Cytokines may also alter host 
metabolism, usually opposing the 
effects of insulin and encouraging a 
catabolic state. 
In addition to producing cytokines 
(and thereby influencing neutrophils, 
endothelial cells, and other cells of 
the host), macrophages directly engulf 
microbes and generate reactive oxygen 
species and antimicrobial peptides. 
They are commonly the principal host 
cells for pathogens that are not easily 
eradicated, including various fungi, 
mycobacteria, and protozoa.
TLRs are expressed by both 
macrophages and neutrophils. They 
are also expressed by dendritic 
cells, specialized phagocytes that 
primarily serve to stimulate adaptive 
immune responses by activating T lymphocytes through cell-surface 
presentation of antigens. As 
discussed below, a subset of dendritic 
cells, the plasmacytoid dendritic 
cells (pDCs), require a special set 
of proteins to properly establish the 
TLR signaling system that detects 
nucleic acids. It may be inferred 
that different cell types transport 
and utilize TLRs in somewhat 
different ways. Certain TLRs are 
expressed in B cells, which can be 
activated by TLR ligands to promote 
mitogenesis. Many ‘non-immune’ 
cell types, including epithelial cells, 
neurons, astrocytes, and fibroblasts, 
also express TLRs and respond to 
their activation. In some cases, as 
in the gut epithelium, the response 
is proliferative. In other cases, it 
resembles the classical inflammatory 
response. The expression and 
function of TLRs in diverse cells 
implies that the innate immune 
response results from the concerted 
actions of multiple cell types rather 
than a few specialized immune 
cell types.TLR signaling
Signal transduction from TLRs 
ultimately induces the expression 
of numerous genes required for the 
inflammatory response, including 
inflammatory cytokines, chemokines  
(a large family of cytokine molecules 
that engage G-protein-coupled 
receptors), antimicrobial molecules 
(e.g. hydrolytic enzymes, 
peptides, proteases), and major 
histocompatibility (MHC) and 
costimulatory molecules important 
for adaptive immune activation. 
TLR signaling depends critically on a 
total of four adaptor proteins— MyD88, 
TIRAP (also called MAL), TICAM1 
(also called TRIF), and TICAM2 
(also called TRAM) — that directly 
bind to activated TLRs and recruit 
downstream signaling components. 
Ligand binding to TLRs is believed to 
alter the association or conformation 
of TLR ectodomains, changes that 
are propagated to the intracellular TIR 
domain of the TLR. Through unknown 
mechanisms, the TIR domains of 
adaptors then associate with receptor 
TIR domains. Some structural data 
have recently revealed a helical 
‘myddosome’ as the active adaptor 
conformation.
With the exception of TLR3, which 
signals exclusively via TICAM1, all 
TLRs utilize a MyD88-dependent 
pathway resulting in the production 
of TNF-a, IL-1, IL-6, and other 
cytokines dependent on NF-kB, and 
also trigger mitogen-activated protein 
(MAP) kinase cascades that lead to 
activation of AP-1 and cyclic AMP 
(cAMP) response element-binding 
protein (CREB). MyD88 can, when 
stimulated by some of the TLRs, 
also activate the transcription factor 
interferon regulatory factor 7 (IRF7), 
leading to the induction of type I 
interferons (IFNs), which are especially 
potent anti-viral cytokines. The 
TICAM1-dependent pathway utilized 
by TLR3 is able to activate NF-kB, 
and additionally activates IRF3 to 
induce type I IFNs. TLR4 can also 
activate the TICAM1-dependent 
pathway from within late endosomes 
following phagocytosis (Figure 2). 
A basic delineation of the pathways 
is depicted in Figure 3. The details of 
TLR signaling have been intensively 
investigated, and much is known 
about the cell-type- and stimulus-
dependent nuances of the pathways. 
Stepping back from these particulars, 
a key point to appreciate is the 
Magazine
R491importance of phospho- and ubiquitin-
dependent interactions for signaling 
from all TLRs; the activities of kinases 
and ubiquitinases dominate the TLR 
signaling cascades and may allow for 
enormous signal amplification, in that 
a few activated TLR complexes are 
able to cause dramatic transcriptional 
changes within a cell.
Post-transcriptional changes also 
occur within cells in response to 
TLR signaling. Well known is the 
enhanced stability and translational 
efficiency of TNF-a mRNA, which is 
poorly transcribed in resting cells 
because of a blockade imposed by an 
 AU-rich element in the 3’ untranslated 
region. The RNA-binding protein 
tristetraprolin appears to control 
TNF-a mRNA stability, whereas T-cell 
intracellular antigen-1 (TIA-1) controls 
translational efficiency. Other cytokine 
mRNAs bear a similar AU-rich element 
and may be subject to similar control. 
Still other molecules, such as the 
zinc-finger-containing ribonuclease 
Zc3h12a, respond to TLR signaling 
and govern the expression of IL-6 by 
causing mRNA decay.
Compartmentalization of TLRs 
that sense nucleic acids
An important feature of the 
TLR signaling system is that 
nucleic-acid-sensing TLRs (TLR3, 
TLR7, TLR8, and TLR9) are localized 
intracellularly, whereas the other 
TLRs (TLR1, TLR2, TLR4, TLR5, and 
TLR6) are expressed predominantly 
on the cell surface. TLRs 3, 7, 8, 
and 9 detect ligands and signal 
from the endosomal compartment, 
where they are trafficked from the 
endoplasmic reticulum (ER) via the 
secretory pathway. The general 
chaperones Gp96 and PRAT4A are 
necessary for trafficking many of the 
TLRs, including TLR7 and TLR9 to 
endolysosomes, and TLR1, TLR2, 
and TLR4 to the plasma membrane. 
A twelve-pass transmembrane-
spanning protein called UNC93B1 
directly binds and is required for 
endolysosomal localization of TLR3, 
TLR7, and TLR9.
Because of their responsiveness to 
nucleic acids, the intracellular TLRs 
are particularly important for detecting 
viruses, some of which cannot be 
sensed by any other mechanism. 
However, intracellular TLRs are equally 
sensitive to host DNA, and trigger 
innate immune responses if exposed 
to it. Since host DNA is usually Figure 3. TLR signaling.  
The MyD88-dependent pathway leading to proinflammatory cytokine production (center) is 
activated in macrophages by all TLRs except TLR3. Upon TLR activation, MyD88 recruits 
IRAK4 through death-domain interactions. IRAK4 phosphorylates IRAK1 and IRAK2 that, in 
turn, activate the E3 ubiquitin ligase TRAF6, which together with UBC13 and UEV1A  
(not depicted) polyubiquitinates NEMO and itself. TRAF6 also activates TAK1. The 
TAK1-associated TAB2 protein serves as a receptor for the polyubiquitin chains on TRAF6 
and NEMO and holds these proteins together. TAK1 phosphorylates IKKb, activating the IKK 
complex to phosphorylate IkB leading to IkB degradation and release of NF-kB. TAK1 also 
activates MKK3 and MKK6, resulting in activation of CREB and AP1. NF-kB, CREB, and AP-1 
transcription factors induce transcription of proinflammatory cytokines, such as TNF-a and 
IL-1. Signaling from TLR3 in macrophages (left) induces IFN-b through a complex of TICAM1, 
TRAF6, and RIP1; the complex associates with TRAF3 to activate TBK1 and IKKe, which, in 
turn, phosphorylate IRF3. Upon TLR3 activation, TRAF6 and RIP1 can also activate NF-kB 
and MAPKs to induce proinflammatory cytokines. pDCs utilize a distinct pathway to elicit 
large amounts of type I IFN, primarily IFN-a (right). Activation of TLR7 or TLR9 in pDCs  
recruits MyD88 and IRAK4, which then interact with TRAF6, TRAF3, IRAK1, IKKa, 
 osteopontin (OPN), and IRF7. IRAK-1 and IKKa phosphorylate and activate IRF7, leading 
to transcription of type I IFN. pDCs also induce proinflammatory cytokine production 
 downstream of TLR7 and TLR9 by signaling through the MyD88-dependent pathway resulting 
in NF-kB activation (center).excluded from endolysosomes, the 
compartmentalization of TLR3, TLR7, 
TLR8 and TLR9 is thought to prevent 
innate immune activation by host DNA 
that could lead to the development of 
autoimmune disease. The strong drive 
to avoid this outcome is underscored 
by additional restrictions on signaling 
from these TLRs. For example, their 
activation and signaling also require 
endosomal acidification, and typically 
occur during a particular stage of 
endosome maturation. Endosomal 
acidification may contribute to the 
processing, such as cleavage, of the TLRs for efficient signaling. Protease-
mediated cleavage of TLR7 and TLR9 
occurs in endolysosomes but not 
in the ER, and in the case of TLR9 
increases its binding to CpG DNA 
and permits recruitment of MyD88 
and initiation of signal transduction. 
Cleavage of TLR3 has not been 
reported.
TLR signaling in pDCs
pDCs express TLR7 and TLR9 to the 
exclusion of all other TLRs, and upon 
TLR7 or TLR9 activation are capable 
of producing type I IFN in quantities 
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greater than that produced by any 
other cell type. These properties 
make pDCs uniquely adapted for 
sensing and responding to viruses. To 
produce abundant type I IFN, pDCs 
utilize a TLR pathway not present 
in macrophages, conventional 
dendritic cells, or B cells. This 
MyD88-dependent pathway leads 
to phosphorylation and activation of 
IRF7, which induces the transcription 
of type I IFN genes (Figure 3).
pDCs also produce 
proinflammatory cytokines 
in response to TLR7 or TLR9 
ligands, using the same MyD88-
dependent pathway that operates 
in macrophages. Type I IFN or 
proinflammatory cytokines are 
preferentially produced by pDCs in 
response to TLR9 activation by one 
of two types of CpG molecule —  
A-type CpG-DNA or B-type CpG-
DNA. Structurally, A-type CpG-
DNA forms aggregates that are 
retained in the early endosomes of 
pDCs, whereas B-type CpG-DNA 
remains monomeric and traffics 
rapidly through early endosomes 
into acidified late endosomes or 
lysosomes. It has now been shown 
that TLR9 engagement by either type 
of CpG-DNA in the early endosome 
leads to IRF7 activation and type I 
IFN production. In contrast, TLR9 
activation in the late endosome 
results in NF-kB activation and 
TNF-a production. Whether different 
viral DNA species are differentially 
trafficked through endolysosomes, 
thereby dictating the ratio of type I 
IFN and proinflammatory cytokines 
generated, remains unknown.
TLR signaling in pDCs is distinctive 
not only because of the existence 
of a special pathway leading to type 
I IFN production, but also because 
establishing this pathway and/or 
the machinery to activate it requires 
a group of proteins not necessary 
in other cell types. In addition to 
the chaperones Gp96, PRAT4A, 
and UNC93B1, lysosomal sorting 
proteins of the AP-3, BLOC-1 and 
BLOC-2 complexes and a twelve-
pass transmembrane spanning 
peptide–proton symporter channel 
called Slc15a4 are required to 
permit TLR9 signaling, leading to 
both type I IFN and proinflammatory 
cytokine production by pDCs. What 
function these proteins serve in 
setting up TLR signaling in pDCs is an open question. Hypotheses 
include aiding in the transport of 
pDC-specific components of the TLR 
signaling pathway to endolysosomes, 
moderating the acidification of 
endolysosomes, eliminating inhibitory 
peptides from endolysosomes, 
and/or serving as transporters of TLR 
ligands to endolysosomes.
Aberrant TLR activation is 
associated with disease
Many diseases are now known to 
be mediated by cytokines, insofar 
as specific cytokine blockade can 
substantially alleviate them. Among 
these diseases are rheumatoid 
arthritis, Crohn’s disease, ankylosing 
spondylitis, and psoriasis, for 
which blockade of TNF-a activity 
is therapeutic. Although TLRs are 
not the only receptors capable 
of initiating TNF-a production, 
they are likely the receptors most 
potent in doing so. The intriguing 
possibility that endogenous ligands 
may exist for TLRs has prompted 
the suggestion that proteins, lipids, 
glycans, and nucleic acids of the host 
might, under some circumstances, 
trigger inflammation in the absence 
of microbial infection, or ‘sterile 
inflammation’. Alternatively, ‘sterile 
inflammatory diseases’ might not 
really be sterile after all, and some 
or all of these diseases might be 
microbe driven.
Perhaps the best case for a 
pathogenic role of TLR signaling 
in a sterile inflammatory disease 
may be seen in systemic lupus 
erythematosus (SLE), modeled in 
mice with mutations such as the 
lymphoproliferation (lpr) allele of Fas 
(Cd95), and the Y-linked accelerator 
of autoimmunity (Yaa). It was 
demonstrated that B lymphocytes 
with specificity for immunoglobulin 
G (IgG) are mitotically activated 
when the IgG that is recognized 
engages DNA or ribonucleoprotein. 
This suggests the existence of an 
autoamplification loop in which a 
B-cell clone with specificity for DNA 
might, if exposed to DNA, internalize 
a TLR ligand, leading to cell 
activation and clonal expansion.
The pathogenic role of TLR7 
in SLE was demonstrated in the 
Faslpr model of the disease, in that 
targeted deletion of Tlr7 markedly 
attenuated disease in this model. 
Consistent with this finding, the Yaa 
locus proved to be a duplication encompassing the Tlr7 gene within 
the pseudoautosomal region of the 
Y chromosome. Hence, an excess 
of TLR7 signaling accelerates SLE, 
while abrogation of TLR7 signaling 
abolishes disease. Similarly, mutation 
at the Unc93b1 locus strongly 
suppressed SLE, as did a Myd88 
mutation. Curiously, Tlr9 knockout 
augmented disease, an observation 
that may indicate competition 
between TLR7 and TLR9 for transport 
to the endosome by UNC93B1. These 
observations indicate that, in SLE, 
TLR7 (and possibly TLR9) signaling 
is pathogenically important. These 
TLRs themselves, and possibly 
components of the system that 
supports TLR signaling within the 
endosome, may be considered 
targets for therapeutic intervention.
In other inflammatory disease 
states, notably the severe systemic 
inflammation and autoimmunity 
triggered by loss of the protein 
tyrosine phosphatase Shp1, TLRs are 
also critically important. Moreover, 
inflammation is initially triggered by 
microbes because germ-free animals 
do not develop disease. MyD88 
signaling appears to be important, 
although not necessarily essential, 
for the inflammatory disease that 
results from loss of regulatory T-cell 
function due to deletion of Foxp3, 
a master regulator of regulatory 
T-cell development. Here, too, the 
importance of microbes might be 
inferred, in that adaptive immune 
responses to microbes may be 
the driving force of disease. 
As specific TLR inhibitors are 
developed, whether antibodies or 
small molecules, we may learn that 
many inflammatory diseases can 
be controlled with a high degree 
of specificity.
Conclusions
Several key concepts define our 
current understanding of TLR function. 
First, TLRs are critical activators of 
the innate immune response, which 
is characterized by inflammation, 
induced in large part by inflammatory 
cytokines produced in a TLR-
dependent manner by macrophages. 
Second, TLR ligands represent all 
known pathogens and bind by diverse 
modes to overall structurally similar 
receptor extracellular domains, 
leading to the recruitment of adaptors 
that initiate signaling cascades. Third, 
the inflammatory response triggered 
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stimuli. We used a form of binocular 
masking to suppress awareness of 
oriented stimuli [8]. Despite initial 
insensitivity when making verbal 
judgements, participants who reached 
as if to grasp perceptually suppressed 
stimuli displayed increasing 
proficiency with training and feedback. 
This was not simply due to practise, 
as another group did not develop 
such proficiency when completing 
a matched number of trials, with 
feedback, while making verbal 
responses; however, this same group 
subsequently developed sensitivity 
when they too completed training with 
reaching and feedback. Our data thus 
reveal a special status for attempts to 
grasp perceptually suppressed stimuli. 
We used presentations of high 
contrast white noise to one eye 
to suppress awareness of pairs 
of oriented lines in the other eye 
(Figure 1 and see Supplemental 
Learning to reach 
for ‘invisible’ visual 
input
Warrick Roseboom  
and Derek H. Arnold
Patients who have suffered damage to 
primary visual cortex can report being 
blind but display some proficiency 
when manually interacting with 
‘unseen’ objects — a phenomenon 
known as blindsight [1–4]. There is 
conflicting evidence about analogous 
situations in normally sighted people 
[5–7]; however, to date no study 
has attempted to assess a directly 
analogous situation, to have normally 
sighted people interact with unseen 
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Figure 1. Example trial sequence, experimental apparatus and data from Experiments 1–3. 
(A) Depiction of a trial sequence with a vertical target stimulus. Target stimuli reached peak 
contrast 2.5 seconds into the trial, accompanied by a tonal pip to prompt the participant to re-
spond. A second pip signalled the conclusion of the trial and, on reaching trials, let participants 
know they could return their hand to a resting position. When feedback was provided, it was 
presented for one second following the five second trial sequence (Supplemental Movie 1). 
(B) Depiction of experimental apparatus from the right rear. Participants sat with their head on 
a chinrest and observed the stimulus presentation via half silvered mirrors. (see Supplemental 
Information for further details). (C) Participant sensitivity (d’) to the target orientation in eight 
blocks of trials from Experiment 1. In the first two blocks of trials, given by the box data points 
in the central panel, participants responded verbally and were given no feedback. In the final 
six blocks of trials (star data points), participants responded by reaching out and pretending 
to grasp the oriented target and were given trial-by-trial feedback. The red line shows a linear 
regression to the data. Bar plots show participants’ overall performance during the first (left 
panel) and last (right panel) two blocks of trials. In these plots a star indicates that this level of 
sensitivity was significantly different from zero. Error bars show ± 1 SEM. (D) and (E) show the 
same as (C) for Experiments 2 and 3, respectively.by TLR activation is a double-edged 
sword, defending against infection but 
also potentially harmful to the host, 
because aberrant activation may lead 
to autoimmunity and inflammatory 
disease. Within the framework of this 
understanding, it is hoped that future 
studies will permit the development of 
targeted therapies for both infectious 
and autoimmune diseases.
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